Achilles Therapeutics (ACHL) Stock Price, News & Analysis

Company Overview

Achilles Therapeutics plc, a biopharmaceutical company, develops precision T cell therapies to treat solid tumors. Its platform identifies mutations formed early in the development of cancer. The company offers PELEUS, a proprietary AI-powered bioinformatics platform, used to identify clonal neoantigens in a patient. It also develops CHIRON, which is in Phase I/IIa clinical trial for use in the treatment of advanced non-small cell lung cancer; and THETIS, a product candidate in Phase I/IIa clinical trial for use in the treatment of metastatic or recurrent melanoma. The company was formerly known as Achilles TX Limited and changed its name to Achilles Therapeutics Plc in February 2021. Achilles Therapeutics Plc was founded in 2016 and is headquartered in London, the United Kingdom.

Key Stats

• Today's Range: $1.05 to $1.06
• 50-Day Range: $0.71 to $1.07
• 52-Week Range: $0.63 to $1.76
• Volume: 7,563 shs
• Average Volume: 453,288 shs
• Market Capitalization: $43.16 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $4.00
• Consensus Rating: Hold

Achilles Therapeutics Stock Analysis - MarketRank™

Achilles Therapeutics scored higher than 56% of companies evaluated by MarketBeat, and ranked 581st out of 963 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.0 / 5
• Analyst Rating: Hold

Consensus Rating

Achilles Therapeutics has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on 1 buy rating, 1 hold rating, and 1 sell rating.

Amount of Analyst Coverage

Achilles Therapeutics has received no research coverage in the past 90 days.

Earnings and Valuation

• Score: 1.3 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Achilles Therapeutics are expected to grow in the coming year, from ($1.70) to ($1.31) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Achilles Therapeutics is -0.64, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Achilles Therapeutics is -0.64, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Achilles Therapeutics has a P/B Ratio of 0.42. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

Short Interest

• Score: 5.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

0.41% of the float of Achilles Therapeutics has been sold short.

Short Interest Ratio / Days to Cover

Achilles Therapeutics has a short interest ratio ("days to cover") of 0.2, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Achilles Therapeutics has recently decreased by 25.07%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Achilles Therapeutics does not currently pay a dividend.

Dividend Growth

Achilles Therapeutics does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

0.41% of the float of Achilles Therapeutics has been sold short.

Short Interest Ratio / Days to Cover

Achilles Therapeutics has a short interest ratio ("days to cover") of 0.2, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Achilles Therapeutics has recently decreased by 25.07%, indicating that investor sentiment is improving significantly.

News and Social Media

• Score: 1.7 / 5
• News Sentiment: -0.01

News Sentiment

Achilles Therapeutics has a news sentiment score of -0.01. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.46 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 6 news articles for Achilles Therapeutics this week, compared to 0 articles on an average week.

MarketBeat Follows

2 people have added Achilles Therapeutics to their MarketBeat watchlist in the last 30 days. This is an increase of 100% compared to the previous 30 days.

Company Ownership

• Score: 0.8 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Achilles Therapeutics insiders have not sold or bought any company stock.

Percentage Held by Insiders

Only 5.38% of the stock of Achilles Therapeutics is held by insiders.

Percentage Held by Institutions

56.38% of the stock of Achilles Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

ACHL Stock Analysis - Frequently Asked Questions

How have ACHL shares performed this year?

Achilles Therapeutics' stock was trading at $0.8890 at the start of the year. Since then, ACHL shares have increased by 18.1% and is now trading at $1.05.
View the best growth stocks for 2024 here.

How were Achilles Therapeutics' earnings last quarter?

Achilles Therapeutics plc (NASDAQ:ACHL) posted its earnings results on Wednesday, August, 14th. The company reported ($0.41) EPS for the quarter, meeting analysts' consensus estimates of ($0.41).

When did Achilles Therapeutics IPO?

Achilles Therapeutics (ACHL) raised $176 million in an initial public offering on Wednesday, March 31st 2021. The company issued 9,800,000 shares at $17.00-$19.00 per share. JPMorgan, BofA Securities, Piper Sandler, Chardan, Oppenheimer & Co. and Kempen & Co. served as the underwriters for the IPO.

Who are Achilles Therapeutics' major shareholders?

Achilles Therapeutics' top institutional investors include BML Capital Management LLC (9.98%).

How do I buy shares of Achilles Therapeutics?

Shares of ACHL stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

What other stocks do shareholders of Achilles Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Achilles Therapeutics investors own include Block (SQ), Digital Turbine (APPS), Palantir Technologies (PLTR), Aquestive Therapeutics (AQST), CRISPR Therapeutics (CRSP), ChargePoint (CHPT) and NVIDIA (NVDA).

Company Calendar

• Last Earnings: 8/14/2024
• Today: 11/21/2024
• Fiscal Year End: 12/31/2024

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Biological products, except diagnostic
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:ACHL
• CUSIP: N/A
• CIK: 1830749
• Web: www.achillestx.com
• Phone: 44-0-20-8154-4600
• Fax: N/A
• Employees: 250
• Year Founded: N/A

Price Target and Rating

• Average Stock Price Target: $4.00
• High Stock Price Target: $6.00
• Low Stock Price Target: $2.00
• Potential Upside/Downside: +273.8%
• Consensus Rating: Hold
• Rating Score (0-4): 2.00
• Research Coverage: 3 Analysts

Profitability

• EPS (Most Recent Fiscal Year): ($1.65)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: $-69,670,000.00
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -54.45%
• Return on Assets: -47.68%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 6.04
• Quick Ratio: 6.04

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $3.49 per share
• Price / Book: 0.31

Miscellaneous

• Outstanding Shares: 41,100,000
• Free Float: 38,889,000
• Market Cap: $43.98 million
• Optionable: Not Optionable
• Beta: 1.35